文献速递免疫规划卫生政策与健康促进

带状疱疹减毒活疫苗:上市后安全性经验十年回顾

Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
PubMed 文献 · Vaccine · 2017-11-22

本文回顾了2006年5月2日至2016年5月1日全球提交至默沙东不良事件全球安全数据库的带状疱疹减毒活疫苗(ZVL)上市后不良事件报告,共23,556份报告,其中93%为非严重事件。主要不良事件为注射部位局部反应(中位发生时间2天)和带状疱疹,整体安全性特征良好,与临床试验及上市后研究一致。

要点

  • 局部注射部位反应是最常见不良事件,中位发生时间2天。
  • 带状疱疹多在接种后2周内报告,按发病时间及病原学考虑为野生型水痘-带状疱疹病毒所致。
  • 经PCR确认为疫苗株Oka/Merck的带状疱疹仅见于免疫功能正常者接种后8个月及4例免疫功能受损者。

核心结论

  • 带状疱疹减毒活疫苗上市后10年安全性特征良好,与临床试验及上市后研究观察一致。

主要发现

  • 共收到23,556份不良事件报告,其中93%为非严重事件。
  • 局部注射部位反应是最常报告的不良事件,中位发生时间为2天,其次为带状疱疹。
  • 多数带状疱疹报告发生在接种后2周内,基于发生时间、带状疱疹发病机制及临床试验数据,考虑由野生型水痘-带状疱疹病毒所致。
  • 经PCR确认为疫苗株Oka/Merck的带状疱疹见于1例免疫功能正常者接种后8个月及4例免疫功能受损者。
  • 播散性带状疱疹报告非常罕见(<1%),其中38%发生在免疫功能受损者;所有经PCR确认为疫苗株Oka/Merck的播散性带状疱疹报告均发生于接种时存在免疫抑制状况和/或接受免疫抑制治疗者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Zoster vaccine is a single dose live, attenuated vaccine (ZVL) indicated for individuals ≥50 years-old for the prevention of herpes zoster (HZ). Safety data from clinical trials and post-licensure studies provided reassurance that ZVL is generally safe and well tolerated. The objective of this review was to provide worldwide post-marketing safety information following 10 years of use and >34 million doses distributed. METHODS: All post-marketing adverse experience (AE) reports received worldwide between 02-May-2006 and 01-May-2016 from healthcare professionals following vaccination with ZVL and submitted to the MSD AE global safety database, were analyzed. RESULTS: A total of 23,556 AE reports, 93% non-serious, were reported. Local injection site reactions (ISRs), with a median time-to-onset of 2 days, were the most frequently reported AEs followed by HZ. The majority of HZ reports were reported within 2 weeks of vaccination and considered, based on time-to-onset, pathogenesis of HZ, and data from clinical trials, to be caused by wild-type varicella-zoster virus (VZV). HZ confirmed by PCR analysis to be VZV Oka/Merck vaccine-strain was identified in an immunocompetent individual 8 months postvaccination and in 4 immunocompromised individuals. Disseminated HZ was reported very rarely (<1%) with 38% occurring in immunocompromised individuals. All reports of disseminated HZ confirmed by PCR as VZV Oka/Merck vaccine-strain were in individuals with immunosuppressive conditions and/or therapy at the time of vaccination. CONCLUSIONS: The safety profile of ZVL, following 10 years of post-marketing use, was favorable and consistent with that observed in clinical trials and post-licensure studies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience. Vaccine. 2017. PMID: 29174682. doi:10.1016/j.vaccine.2017.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。